Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

  • Technology appraisal guidance
  • TA979
  • Published: 

History

Documents created during the development process.

Declaration of interests

Final draft guidance

Draft guidance

Committee meetings

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators